Methods We developed a highly potent and selective oral STAT6 degrader, KT-621, and assessed its functions in vitro in human primary cells, and in vivo in intranasal house dust mite (HDM)-induced asthma models in both prophylactic and treatment regimens. Results KT-621 potently and selectively...
STAT6degraderNurixTherapeutics/赛诺菲炎症(未指明)临床前 WO2024238598A2RecludixPharma癌症;炎症(未指明)临床前 PM-43IMDAnderson/AtraposTherapeutics哮喘;AD;特发性肺纤维化;鼻-鼻窦炎临床前 REX-2787RecludixPharma癌症;炎症(未指明)临床前 REX-4671RecludixPharma癌症;炎症(未指明)临床前 ...
28、PD;AD;哮喘等I期临床AK-1690UniversityofMichigan癌症临床前STAT6degraderNurixTherapeutics/赛诺菲炎症(未指明)临床前WO2024238598A2RecludixPha强生就炎症疾病创新靶点STAT6达成12.47亿美元合作rma癌症;炎症(未指明)临床前小分子抑制剂PM-43IMDAnderson/AtraposTherapeutics哮喘;AD;特发性肺纤维化;鼻-鼻窦炎临床前RE...
“We are particularly excited about the initiation of the Phase 1 trial for KT-621, our first-in-class STAT6 degrader. This is a target that perfectly fits the value proposition of oral degraders with biologics-like activity, and we are excited and proud to be the first company to ...